ArticleBMC cancer2025

Investigator-initiated phase I trial of an oligonucleotide therapeutic targeting long noncoding RNA TUG 1 for recurrent glioblastoma.

Shoichi Deguchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.